Benchmark Holdings PLC said it does not expect to complete a commercial licensing deal before its September year-end.
As a result, the aquaculture health group is accelerating the programme of disposals and structural efficiencies.
The discussions with third parties about licensing its non-core animal vaccines have been subject to delays, Benchmark said.
Conditions in the shrimp and seabass markets have been challenging in 2019 after a record shrimp harvest last year has forced customers to cut production, which has knocked demand for products such as fish feed, vaccines and water treatments.
The company is in the midst of a five-year strategy to drive growth and profitability.